[go: up one dir, main page]

WO2005000845A3 - Derives bicycliques utilises en tant qu'antagonistes des recepteurs nk-1 et nk-2 - Google Patents

Derives bicycliques utilises en tant qu'antagonistes des recepteurs nk-1 et nk-2 Download PDF

Info

Publication number
WO2005000845A3
WO2005000845A3 PCT/EP2004/051210 EP2004051210W WO2005000845A3 WO 2005000845 A3 WO2005000845 A3 WO 2005000845A3 EP 2004051210 W EP2004051210 W EP 2004051210W WO 2005000845 A3 WO2005000845 A3 WO 2005000845A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
bicyclic derivatives
neurokinin
receptors
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/051210
Other languages
English (en)
Other versions
WO2005000845A2 (fr
Inventor
Giuseppe Arnaldo Mari Giardina
Stefania Gagliardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NiKem Research SRL
Original Assignee
NiKem Research SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NiKem Research SRL filed Critical NiKem Research SRL
Publication of WO2005000845A2 publication Critical patent/WO2005000845A2/fr
Publication of WO2005000845A3 publication Critical patent/WO2005000845A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des nouveaux dérivés de formule (1) qui présentent une activité antagoniste envers les récepteurs neurokinine 1 (NK-1) et neurokinine 2 (NK-2), ainsi que le procédé de préparation de ceux-ci. Ces composés sont utiles dans la prévention et/ou le traitement des maladies associées à la stimulation des récepteurs NK-1 et NK-2.
PCT/EP2004/051210 2003-06-25 2004-06-23 Derives bicycliques utilises en tant qu'antagonistes des recepteurs nk-1 et nk-2 Ceased WO2005000845A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2003A001292 2003-06-25
IT001292A ITMI20031292A1 (it) 2003-06-25 2003-06-25 Derivati biciclici nk-2 antagonisti selettivi.

Publications (2)

Publication Number Publication Date
WO2005000845A2 WO2005000845A2 (fr) 2005-01-06
WO2005000845A3 true WO2005000845A3 (fr) 2005-04-07

Family

ID=30131291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/051210 Ceased WO2005000845A2 (fr) 2003-06-25 2004-06-23 Derives bicycliques utilises en tant qu'antagonistes des recepteurs nk-1 et nk-2

Country Status (2)

Country Link
IT (1) ITMI20031292A1 (fr)
WO (1) WO2005000845A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835426B2 (en) 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
US9079861B2 (en) 2007-11-07 2015-07-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009075835A1 (fr) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc Inhibiteurs cycliques d'urée de la 11-hydroxystéroïde déhydrogénase 1
ES2421537T3 (es) 2008-05-01 2013-09-03 Vitae Pharmaceuticals Inc Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
CA2729998A1 (fr) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibiteurs de la 11 beta-hydroxysteroide deshydrogenase 1
CA2730499A1 (fr) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibiteurs cycliques de la 11 beta-hydroxysteroide deshydrogenase 1
WO2010089303A1 (fr) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh Inhibiteurs cycliques de la 11β-hydroxystéroïde déshydrogénase de type 1
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
EP2440537A1 (fr) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déshydrogénase 1 basée sur la structure 1,3-oxazinan-2-one
WO2011159760A1 (fr) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation
EP2585444B1 (fr) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones comme inhibiteurs de 11-beta -hsd1 pour le traitement de troubles métaboliques
MX2013004699A (es) 2010-11-02 2013-05-22 Boehringer Ingelheim Int Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044154A1 (fr) * 2000-11-28 2002-06-06 Glaxosmithkline Spa Nouveaux composés
WO2002083663A1 (fr) * 2001-04-11 2002-10-24 Glaxosmithkline S.P.A. Derives de quinoline-4-carboxamide comme antagonistes de recepteurs de nk-3 et nk-4

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044154A1 (fr) * 2000-11-28 2002-06-06 Glaxosmithkline Spa Nouveaux composés
WO2002083663A1 (fr) * 2001-04-11 2002-10-24 Glaxosmithkline S.P.A. Derives de quinoline-4-carboxamide comme antagonistes de recepteurs de nk-3 et nk-4

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLANEY, F.E. ET AL.: "Stepwise Modulation of Neurokinin-3 and Neurokin-2 Receptor Affinity and Selectivity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, 2001, pages 1675 - 1689, XP002301972 *
WERMUTH ET AL: "The Practise of Medicinal Chemistry", PRACTICE OF MEDICINAL CHEMISTRY, XX, XX, 1996, pages 203 - 237, XP002190259 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835426B2 (en) 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
US9079861B2 (en) 2007-11-07 2015-07-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1

Also Published As

Publication number Publication date
ITMI20031292A1 (it) 2004-12-26
WO2005000845A2 (fr) 2005-01-06
ITMI20031292A0 (it) 2003-06-25

Similar Documents

Publication Publication Date Title
WO2005000845A3 (fr) Derives bicycliques utilises en tant qu'antagonistes des recepteurs nk-1 et nk-2
WO2004032852A3 (fr) Procedes permettant de traiter l'arythmie cardiaque et de prevenir la mort due a l'arythmie cardiaque au moyen d'antagonistes du ngf
MXPA05009508A (es) Derivados de nicotinamida 6-substituida como antagonistas de receptor opioide.
IL161074A0 (en) Lactam derivatives as antagonists for human 11cby receptors
WO2006005609A3 (fr) Derives d'oxindole substitues, et medicaments les renfermant
CA2503767A1 (fr) Pyridopyrrolizine et derives de pyridoindolizine
WO2002081448A1 (fr) Derive benzamidine
WO2001066534A3 (fr) Antagonistes du recepteur d'histamine-3 diamino cycliques et bicycliques
ZA200703579B (en) Potentiators of glutamate receptors
WO2003024401A3 (fr) Piperazinones de modulation de l'activite des recepteurs des chimiokines
AU2003281213A1 (en) 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough
WO2003006604A3 (fr) Peptides cycliques agonistes puissants et selectifs de recepteur de melanocortine-4
WO2004014893A3 (fr) Quinolones anti-microbiens, leurs compositions et utilisation
AU2003229772A1 (en) Derivatives of 2-(1-benzyl-1h-pyrazolo (3, 4-b)pyridine-3yl) -5-(4-pyridinyl)-4-pyrimidine amine and the use thereof as guanylate cyclase stimulators
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
WO2004074247A3 (fr) Antagonistes du recepteur de l'adenosine a1
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
AU2003239389A1 (en) Opioid receptor antagonists
CA2474510A1 (fr) Heterocycles tricycliques fusionnes utilises dans le traitement de troubles hyperproliferatifs
WO2004022540A3 (fr) Compose de pyridazinone et son utilisation pharmaceutique
WO2003066621A8 (fr) Derives de piperidine et leur utilisation en tant qu'antagonistes des tachykinines
WO2005065150A3 (fr) Heterocycles mutagenes
BR0307156A (pt) Derivado de pirimidina bicìclica fundida, composto, antagonistas de receptores e agentes profiláticos e terapêuticos

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application